Biotech Startups

Cryosmetics produces a body oil made from natural vegetable oils and lipid-soluble compounds derived from chamomile and calendula flowers for skincare. The product is formulated with organic and agroecological ingredients, free of synthetic additives, and is suitable for all skin types.

1 investor

Cryostasis develops the Woolii SU (Subzero Unfrozen) platform, a preservation system that stores cell therapy products at subzero temperatures without freezing or cryoprotectants. It targets cell manufacturers, integrating into fill & finish and final-mile delivery to preserve cell potency and simplify shipping and handling.

1 investor

CryoTherapeutics is developing a device-based treatment for vulnerable (high-risk) atherosclerotic plaque in the coronary arteries, a condition associated with coronary artery disease and heart attacks. The company targets a gap in cardiac care where existing options such as stents do not address the underlying plaque pathology.

1 investor

Cultimate Foods develops CultiSense, a natural meat flavor ingredient produced through cellular agriculture for use in food manufacturing. The company targets food manufacturers seeking authentic, sustainable alternatives to conventional animal-derived flavor components.

1 investor

Cultipharm produces and customizes botanical extracts and active ingredients grown through vertical farming in a controlled indoor laboratory (fitotrone). It offers traceable, customizable "Superactive" botanical ingredients and works on preserving ancient or endangered plant species.

1 investor

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specializing in polymer- and lipid-based non-viral drug delivery systems for biotech and pharmaceutical companies. The company develops and manufactures lipid nanoparticles, polymer nanoparticles, and delivery components from early development through GMP-certified commercial manufacturing for oncology, cell and gene therapy, and vaccine applications.

1 investor

Cure Kids is a New Zealand charity that raises funds to support medical research into child health conditions such as preterm health, childhood cancers, rheumatic heart disease, and neurological disorders. It has funded over $70M of research across more than 700 projects, currently backing over 100 active projects led by researchers across Aotearoa.

1 investor

CureAge Therapeutics develops a cell delivery platform targeting Schwann cells for treating neurofibromatosis type 1 (NF1) peripheral tumors. The company emerged from a partnership between the Children's Tumor Foundation and Deep Science Ventures to address unmet needs in the neurofibromatosis patient community.

1 investor

Curesign is a medical device company developing a system that combines sensors with signal processing and big data tools to help oncologists tailor patient-specific cancer treatments. Its technology has been demonstrated in preclinical studies and is being developed into a commercial product for oncology trials.

1 investor

Curesponse applies science and technology to improve cancer treatment, bringing together medical executives, scientists, and clinical and regulatory experts. The company operates laboratories in the UK and Israel to support oncology treatment decisions.

1 investor

Curetis develops molecular diagnostic systems for detecting pathogens and antimicrobial resistance markers in severe infections. Its testing solution provides physicians with rapid results to guide treatment decisions for infectious diseases.

1 investor

Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.

1 investor

Curia provides R&D and manufacturing services to help clients address complex scientific and production challenges. The company employs over 3,000 scientists and specialists across 20 global locations.

1 investor

Curida is a contract manufacturing organization specializing in pharmaceutical liquid formulations and biologics, operating under strict EU GMP and ISO certifications to ensure product quality and compliance. The company serves pharmaceutical companies and life science organizations requiring manufacturing and technology transfer services.

1 investor

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer. The company works with specialist partners in chemistry and regulatory affairs to advance its clinical pipeline.

1 investor

Curiosis is a biotech company focusing on bio-pharmaceutical supply chain components and materials. The company operates in the medical device and biotechnology sector in South Korea.

1 investor

Curiox Biosystems develops centrifuge-free, pipette-based cell washing technology that replaces manual centrifugation with software-defined flow executed on standard liquid handling platforms. Its tools serve research labs performing flow cytometry, immune monitoring, and cell preparation workflows in life sciences.

1 investor

Curis is a biopharmaceutical company focused on drug development and clinical advancement. The company's board includes experienced leaders in oncology, immunology, dermatology, and pharmaceutical development.

1 investor

Curtana Pharmaceuticals develops small molecule drugs targeting cancer stem cells in brain tumors, specifically gliomas and related CNS malignancies. The company focuses on OLIG2 inhibition to overcome treatment resistance and recurrence in pediatric and adult brain cancers.

1 investor

Curve builds BIOBRIC, a modular production system for precision fermentation and cell cultivation designed to reduce the capital and operating costs of biomanufacturing for lower-margin industries such as food, cosmetics, materials, and functional ingredients. It combines hardware with data simulations for strain and process optimization, and licenses validated setups to producers scaling commercial protein and bioidentical ingredient production.

1 investor

Cutanos is a biotechnology company developing a Langerhans Cell Targeted Delivery System (LC-TDS) that uses a langerin-specific glycomimetic ligand to direct lipid nanoparticle and mRNA/protein formulations to specific skin-resident dendritic cells for vaccines and immunotherapies. The platform is administered via minimally invasive microneedles or microinjectors and targets next-generation vaccines, cancer immunotherapy, and autoimmune disease applications.

1 investor

CutisBio applies synthetic biology and biomanufacturing to develop microbial strains, biomaterials, and production processes for use in health, beauty, and fashion applications. It works with manufacturing and distribution partners to bring materials to market, with a stated focus on longevity and healthier lives.

1 investor

CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.

1 investor

CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.

1 investor